Marshall & Sullivan Inc. WA Grows Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Marshall & Sullivan Inc. WA raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 1.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 19,232 shares of the medical instruments supplier’s stock after buying an additional 284 shares during the quarter. Becton, Dickinson and Company comprises 2.8% of Marshall & Sullivan Inc. WA’s holdings, making the stock its 17th largest position. Marshall & Sullivan Inc. WA’s holdings in Becton, Dickinson and Company were worth $5,077,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Heritage Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company by 152.4% in the fourth quarter. Heritage Wealth Management LLC now owns 106 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 64 shares during the last quarter. Tucker Asset Management LLC purchased a new position in Becton, Dickinson and Company during the first quarter valued at approximately $37,000. Advisors Asset Management Inc. purchased a new position in Becton, Dickinson and Company during the first quarter valued at approximately $40,000. Accel Wealth Management raised its position in Becton, Dickinson and Company by 254.0% during the first quarter. Accel Wealth Management now owns 177 shares of the medical instruments supplier’s stock valued at $44,000 after acquiring an additional 127 shares in the last quarter. Finally, Grey Fox Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $47,000. 86.72% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. Piper Sandler raised their price objective on Becton, Dickinson and Company from $290.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, July 24th. Raymond James dropped their price objective on Becton, Dickinson and Company from $305.00 to $304.00 and set an “outperform” rating on the stock in a report on Friday, August 4th. Citigroup raised their price objective on Becton, Dickinson and Company from $260.00 to $282.00 and gave the company a “neutral” rating in a report on Monday, August 21st. Finally, Barclays raised their price objective on Becton, Dickinson and Company from $284.00 to $303.00 and gave the company an “overweight” rating in a report on Monday, August 7th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $288.44.

Insider Activity at Becton, Dickinson and Company

In related news, EVP David Hickey sold 2,974 shares of the business’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $277.85, for a total value of $826,325.90. Following the sale, the executive vice president now owns 4,199 shares in the company, valued at approximately $1,166,692.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, EVP David Hickey sold 2,974 shares of the business’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $277.85, for a total transaction of $826,325.90. Following the completion of the transaction, the executive vice president now directly owns 4,199 shares of the company’s stock, valued at approximately $1,166,692.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Claire Fraser sold 848 shares of the business’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $281.66, for a total value of $238,847.68. Following the transaction, the director now directly owns 21,608 shares of the company’s stock, valued at $6,086,109.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,581 shares of company stock worth $1,551,429. 0.31% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $264.64 on Tuesday. Becton, Dickinson and Company has a one year low of $215.90 and a one year high of $287.32. The company has a market cap of $76.77 billion, a price-to-earnings ratio of 48.03, a PEG ratio of 2.19 and a beta of 0.57. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.73 and a current ratio of 1.25. The business’s 50 day moving average price is $272.46 and its 200 day moving average price is $258.10.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.96 EPS for the quarter, beating analysts’ consensus estimates of $2.89 by $0.07. Becton, Dickinson and Company had a return on equity of 13.24% and a net margin of 8.73%. The company had revenue of $4.88 billion for the quarter, compared to the consensus estimate of $4.84 billion. During the same quarter in the previous year, the business earned $2.66 earnings per share. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. On average, research analysts predict that Becton, Dickinson and Company will post 12.23 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a $0.91 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $3.64 annualized dividend and a dividend yield of 1.38%. Becton, Dickinson and Company’s dividend payout ratio is presently 66.06%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.